Recent Research Analysts’ Ratings Updates for Zoetis (ZTS)

Several analysts have recently updated their ratings and price targets for Zoetis (NYSE: ZTS):

• 7/6/2026 – Zoetis had its price target lowered by HSBC Holdings plc from $140.00 to $95.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Zoetis had its price target lowered by Barclays PLC from $136.00 to $85.00. They now have an “equal weight” rating on the stock.
• 6/30/2026 – Zoetis had its price target lowered by TD Cowen from $150.00 to $104.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Zoetis had its price target lowered by Stifel Nicolaus from $95.00 to $85.00. They now have a “hold” rating on the stock.
• 6/12/2026 – Zoetis was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/27/2026 – Zoetis had its “hold” rating reaffirmed by Argus.
• 5/22/2026 – Zoetis had its price target lowered by Stifel Nicolaus from $105.00 to $95.00. They now have a “hold” rating on the stock.
• 5/18/2026 – Zoetis had its price target lowered by Citigroup Inc. from $145.00 to $112.00. They now have a “buy” rating on the stock.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is currently 35.16%.

Insider Activity

In related news, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.